RxDoctor Payments Data

Felicia Meila, MD

Internal Medicine · Pawtucket, RINPI 1720049802

Payments from drug & device makers

$1,556in general payments, 2019–2025

Across 82 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$383
  • AstraZeneca$203
  • Pfizer$140
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$124
  • Lilly USA, LLC$84
  • GSK$80
  • plus $541 from 17 others

What the payments were for

  • Food & beverage$1,556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,556 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$107,665
Medicare patients
227
Services billed
3,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin181$125,171
EliquisApixaban108$83,236
OzempicSemaglutide65$64,454
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$48,570
TrulicityDulaglutide32$29,501
ProliaDenosumab16$28,221
MounjaroTirzepatide19$18,886
Breo ElliptaFluticasone/Vilanterol27$18,787
SymbicortBudesonide/Formoterol Fumarate31$14,939
XareltoRivaroxaban18$12,584
RybelsusSemaglutide12$10,773
Spiriva HandihalerTiotropium Bromide13$9,000
Incruse ElliptaUmeclidinium Bromide13$8,043
SynthroidLevothyroxine Sodium84$7,416
Omeprazole452$6,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$66$125,171181 claims
PfizerEliquis, Premarin$140$89,809124 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$80$75,401110 claims
Novo NordiskOzempic, Rybelsus$69$75,22777 claims
Lilly USA, LLCTrulicity, Mounjaro$84$48,38751 claims
AmgenProlia$43$28,22116 claims
AstraZenecaSymbicort$203$14,93931 claims
Johnson & JohnsonXarelto$49$12,58418 claims
AbbVieSynthroid$383$7,41684 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Pawtucket

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →